{"id":"W4286491901","doi":"10.1111/bjh.18368","title":"A phase 2, multicentre, open‐label trial (<scp>ACE‐LY</scp>‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Adverse effect; Discontinuation; Refractory (planetary science); Hazard ratio; Febrile neutropenia; Phases of clinical research; Progression-free survival; Surgery; Confidence interval; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001481599,0.0002602356,0.001683675,0.0005038977,0.0001600039,0.00004842439,0.0008021461,0.0001976951,0.0005818077],"category_scores_gemma":[0.002559754,0.0002403585,0.0001318755,0.0007695113,0.0003469529,0.0002946189,0.0005465517,0.0009603167,0.000009352802],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.00429506,"about_ca_system_score_gemma":0.01062794,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006278935,"about_ca_topic_score_gemma":0.0001853883,"domain_scores_codex":[0.9949856,0.0007908477,0.001643515,0.0004229159,0.001396062,0.0007611068],"domain_scores_gemma":[0.9964952,0.0009438806,0.001229969,0.0003994533,0.0005458718,0.0003856157],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5117402,0.06107184,0.005914886,0.0008330291,0.001188724,0.3173925,0.001510165,0.00003446887,0.0003556098,0.0001194246,0.03731136,0.06252775],"study_design_scores_gemma":[0.8603944,0.017692,0.002135868,0.0007755698,0.0002164053,0.1064284,0.0009549347,0.0004975585,0.0002937744,0.00002145252,0.0104532,0.0001364499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959072,0.00132848,0.00003856052,0.0001601906,0.0004959521,0.001625229,0.00007541175,0.00001276084,0.0003561898],"genre_scores_gemma":[0.9963971,0.0002306711,0.001878138,0.0002394446,0.0001099651,0.0000634059,0.00005117593,0.00007029279,0.0009598184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3486542,"threshold_uncertainty_score":0.9995273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03317684450859787,"score_gpt":0.3337321386956786,"score_spread":0.3005552941870808,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}